- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03422484
SCORE of Medication Error in Internal Medecin Unit (SCOREME)
23. april 2018 opdateret af: University Hospital, Montpellier
Developpemment of a Score to Assess Risk of Medication Errors in Internal Medecin Unit
Transfers between interfaces of care are recognized as a source of medication discrepancies, medication errors (MEs) and potentially adverse drug events.
ME are very common at hospital and may have important clinical and economic consequences.
The lack and loss of medication information and communication between health professionals at points of care transition may often lead to ME.
According to the literature, up to two thirds of medication histories contain at least one error.
Some studies have compared pharmaceutical team with physician or nurse on the detection of UMD or ME and have reported that pharmacists were one of the best health care providers to establish medication history.
To improve medication safety and decrease MEs rate, several institutions have recommended to develop medication reconciliation at all transition points such as admission, transfer and discharge.
Medication reconciliation is the process that compares a patient's medication order to all medications that the patient has been taking and should take at admission, transfer and discharge of hospitalization.
Medication reconciliation programs led by pharmacists are effective to reduce medications discrepancies.
However, studies evaluating the efficacy of medication reconciliation program are very heterogeneous in terms of populations, definitions and methodology.
Thus, proportion of ME differs enormously between studies, ranging from under 10% to over 60% at admission of hospitalization.
Elderly patients with their numerous comorbidities associated with polypharmacy, such as patients of internal medecin unit, are at high risk of ME and at risk of safety issues.
However, medication reconciliation process is very time consuming with an average of 30 minutes by patient.
Thereby, review of all inpatients within 24 hours of admissions is very difficult or impossible.
Targeting "high-risk situation" and "high-risk patient" are crucial to detect ME before causing harm.
Therefore, evaluating the risk of MEs and their potential consequences in specific population of internal medicine unit using a validated medication reconciliation process seems of utmost importance for internal medicine specialist clinical practice and the decrease of ME rate.
Consequently, the aim of our study was to (i) evaluate the prevalence of ME in an internal medicine unit at admission of hospitalization, (ii) determine the type of medication involved and the potential clinical impact of ME and (iii) identify factors associated with a risk of ME and serious ME.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Observationel
Tilmelding (Faktiske)
1957
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Montpellier, Frankrig, 34295
- Uhmontpellier
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Study population was composed of patient hospitalized in internal medecine unit of Montpellier University hospital.
Beskrivelse
Inclusion criteria:
- Patients aged above 18 years old, admitted to the department during the study period and hospitalized for at least 24 hours
Exclusion criteria:
- NA
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
People with at least one medication error
People with at least one medication error at hospital admission
|
Detection and correction of medication error at hospital admission
|
|
People without medication error at hospital admission
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
number of medication error
Tidsramme: 1 day
|
number of medication error at hospital admission detected by clinical pharmacist during medication reconciliation process
|
1 day
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
number of variable associated to the risk of ME
Tidsramme: 1 day
|
number of variable associated to the risk of ME detected by logistic regression analysis
|
1 day
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Cyril BREUKER, University Hospital, Montpellier
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. maj 2012
Primær færdiggørelse (Faktiske)
1. november 2017
Studieafslutning (Faktiske)
1. januar 2018
Datoer for studieregistrering
Først indsendt
26. januar 2018
Først indsendt, der opfyldte QC-kriterier
2. februar 2018
Først opslået (Faktiske)
5. februar 2018
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
24. april 2018
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
23. april 2018
Sidst verificeret
1. februar 2018
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- RECHMPL18_0030
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
UBESLUTET
IPD-planbeskrivelse
NC
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .